Moderna announced its decision to cease development of its vaccine mRNA-1647, which was being designed to treat birth defects ...

Less than 1 percent of clinical trials include pregnant or breastfeeding people. Experts say that needs to change ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Moderna stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women.

A key question for investors going forward will be whether Moderna's other latent virus vaccines for Epstein-Barr and ...

Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once ...

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

Moderna said on Wednesday it would stop developing its experimental vaccine to prevent cytomegalovirus, a virus that can cause birth defects, after it failed to meet the main goal of a late-stage ...

Moderna had hoped its shot would be at least 49% effective at preventing CMV infections, substantially reducing the risk of ...

bDepartment of Reproductive Medicine, Division of Gynecology and Reproduction, Karolinska University Hospital, Stockholm, Sweden cCentre for Pharmacoepidemiology, Department of Medicine Solna, ...

bDepartment of Epidemiology, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA cInstitute of Chinese Medical Sciences, University of Macau, ...

1 Department of Infectious Diseases, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China 2 National Clinical Research Center for Infectious Diseases, Shenzhen Clinical Research ...